Skip to main content

Table 6 Summary of adverse events in the safety analysis set

From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

 

TCZ-SC group, n (%)

csDMARDs-alone group, n (%)

n

358

336

AEs

127 (35.5)

99 (29.5)

Drug-related AEs

85 (23.7)

Serious AEs

32 (8.9)

11 (3.3)

Serious drug-related AEs

21 (5.9)

AEs leading to discontinuation of study treatment

33 (9.2)

28 (8.3)

Drug-related AEs leading to discontinuation of study treatment

29 (8.1)

  1. AE adverse event, csDMARD conventional synthetic disease-modifying antirheumatic drug, TCZ-SC tocilizumab by subcutaneous injection